Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed the 8-week double-blind treatment period of study LYC-30937-2001~* Male and females of childbearing potential must agree to use adequate birth control during the study and for 30 days after discontinuing study drug~* Non-pregnant, non-lactating females who are not planning to become pregnant while enrolled in this study~* Investigator considers it safe and potentially beneficial to participate~* Ability to provide written informed consent and to be compliant with study schedule~Exclusion Criteria:~* Subjects who completed study LYC-30937-2001, but who experienced a serious adverse event that was considered related to investigational product, has an unstable medical condition, or for any other reason in the opinion of the investigator should not participate in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LYC-30937-EC (Type: EXPERIMENTAL): LYC-30937-EC 25 mg by mouth once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).